Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Wiley BROS. Aintree Capital LLC

Wiley BROS. Aintree Capital LLC lessened its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 6.6% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 7,783 shares of the biopharmaceutical company’s stock after selling 550 shares during the period. Wiley BROS. Aintree Capital LLC’s holdings in Bristol-Myers Squibb were worth $498,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. True Wealth Design LLC acquired a new position in Bristol-Myers Squibb during the 4th quarter worth approximately $26,000. GoalVest Advisory LLC acquired a new position in Bristol-Myers Squibb during the 1st quarter worth approximately $29,000. Coppell Advisory Solutions Corp. acquired a new position in Bristol-Myers Squibb during the 4th quarter worth approximately $31,000. Live Oak Investment Partners acquired a new position in Bristol-Myers Squibb during the 4th quarter worth approximately $33,000. Finally, First Personal Financial Services grew its holdings in Bristol-Myers Squibb by 67.8% during the 1st quarter. First Personal Financial Services now owns 495 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 200 shares in the last quarter. Institutional investors and hedge funds own 74.98% of the company’s stock.

Bristol-Myers Squibb Stock Performance

BMY stock traded down $0.14 on Thursday, hitting $59.51. The company’s stock had a trading volume of 2,954,745 shares, compared to its average volume of 8,790,276. The firm has a 50 day moving average of $61.88 and a two-hundred day moving average of $65.33. Bristol-Myers Squibb has a 1 year low of $59.44 and a 1 year high of $81.43. The stock has a market cap of $124.32 billion, a price-to-earnings ratio of 15.87, a price-to-earnings-growth ratio of 1.58 and a beta of 0.42. The company has a current ratio of 1.39, a quick ratio of 1.28 and a debt-to-equity ratio of 1.08.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.75 EPS for the quarter, missing analysts’ consensus estimates of $1.99 by ($0.24). The firm had revenue of $11.23 billion for the quarter, compared to analysts’ expectations of $11.81 billion. Bristol-Myers Squibb had a return on equity of 50.51% and a net margin of 17.62%. The firm’s quarterly revenue was down 5.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.93 EPS. Equities analysts predict that Bristol-Myers Squibb will post 7.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Wells Fargo & Company lowered their target price on shares of Bristol-Myers Squibb from $78.00 to $65.00 and set an “equal weight” rating for the company in a report on Friday, July 28th. HSBC assumed coverage on shares of Bristol-Myers Squibb in a report on Friday, July 14th. They issued a “reduce” rating and a $56.00 target price for the company. Credit Suisse Group lowered their target price on shares of Bristol-Myers Squibb from $72.00 to $66.00 in a report on Wednesday, July 12th. StockNews.com cut shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Friday, September 1st. Finally, Daiwa Capital Markets assumed coverage on shares of Bristol-Myers Squibb in a report on Wednesday, June 28th. They issued an “outperform” rating and a $70.00 target price for the company. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $71.14.

Insiders Place Their Bets

In other Bristol-Myers Squibb news, EVP Ann Powell sold 17,986 shares of the company’s stock in a transaction on Thursday, August 24th. The shares were sold at an average price of $61.25, for a total transaction of $1,101,642.50. Following the completion of the transaction, the executive vice president now owns 27,868 shares in the company, valued at approximately $1,706,915. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, EVP Robert M. Plenge sold 732 shares of the stock in a transaction dated Thursday, August 3rd. The shares were sold at an average price of $61.14, for a total value of $44,754.48. Following the completion of the transaction, the executive vice president now owns 6,584 shares in the company, valued at approximately $402,545.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Ann Powell sold 17,986 shares of the stock in a transaction dated Thursday, August 24th. The shares were sold at an average price of $61.25, for a total transaction of $1,101,642.50. Following the completion of the transaction, the executive vice president now owns 27,868 shares of the company’s stock, valued at approximately $1,706,915. The disclosure for this sale can be found here. 0.09% of the stock is owned by insiders.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.